AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

TRISTEL PLC

Regulatory Filings Apr 23, 2018

7990_rns_2018-04-23_a089eb7c-a2b7-49b8-a145-b58016fc0905.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6996L

Tristel PLC

23 April 2018

Tristel plc

("Tristel" or "the Company")

EPA approval received

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that the United States Environmental Protection Agency ("EPA") has registered its foam-based chlorine dioxide product, Duo. This registration enables Tristel to market Duo to clean and disinfect hard, non-porous surfaces.  The federal registration will be followed by state-by-state approvals which the Company expects to complete by the end of 2018.  The Company anticipates first revenues from the United States during its 2018-19 financial year.

Paul Swinney, CEO of Tristel plc, comments: "We have achieved our first United States regulatory approval, and we will continue to pursue further registrations with the EPA and the Food and Drug Administration ("FDA") to build a broadly-based business in the USA.

"We recently announced that we have appointed Parker Laboratories Inc to manufacture Duo in its FDA approved facility in New Jersey, and to sell Duo into the ultrasound marketplace in which they have national sales coverage. We will sell our products through different channels into other clinical areas in the USA hospital market.

"This first United States approval is a very significant step for our Company as it enables us to access the largest healthcare market in the world. It has been our long-held ambition to be recognised as a global brand in the infection prevention industry. An active presence in the United States is necessary to achieve this ambition, and now we can build upon the foundation stone laid in our collaboration with Parker to progress confidently towards our goal."

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:       

## Tristel plc Tel: 01638 721 500
Paul Swinney, Chief Executive Officer
Liz Dixon, Finance Director
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
finnCap Tel: 020 7220 0500
Geoff Nash/ Giles Rolls (Corporate Finance)
Alice Lane (Corporate Broking)

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFKBDNQBKDPQB

Talk to a Data Expert

Have a question? We'll get back to you promptly.